Immune inactivation by VISTA predicts clinical outcome and therapeutic benefit in muscle-invasive bladder cancer

BACKGROUND: V domain Immunoglobulin suppressor of T cell activation (VISTA) has been proved to be a novel immune checkpoint molecule that positively regulates T cell infiltration in several malignancies. However, the clinical impact of VISTA on muscle-invasive bladder cancer (MIBC) patients remains...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Wandi, Liu, Zhaopei, Jin, Kaifeng, Shao, Fei, Zeng, Han, Wang, Yiwei, Zhu, Yu, Xu, Le, Wang, Zewei, Chang, Yuan, Zhang, Weijuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10347783/
https://www.ncbi.nlm.nih.gov/pubmed/37452272
http://dx.doi.org/10.1186/s12885-023-11157-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10347783/
https://www.ncbi.nlm.nih.gov/pubmed/37452272
http://dx.doi.org/10.1186/s12885-023-11157-x

Ejemplares similares